search
Back to results

Discontinuation Study Of Citalopram (Antidepressant) in Depressed Adolescents

Primary Purpose

Major Depression

Status
Withdrawn
Phase
Phase 3
Locations
Canada
Study Type
Interventional
Intervention
Citalopram
Sponsored by
Sunnybrook Health Sciences Centre
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Major Depression

Eligibility Criteria

13 Years - 18 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Diagnosis of major Depression. Age 13-18. A score of > 16 on the 17 item Hamilton Depression Scale or a score of > 12 on the 17 items plus a score of >7 on the atypical items. Males and females. Outpatient at initiation of double blind treatment phase. Ability to give informed consent. Exclusion Criteria: Past or current hypomanic or manic episode. Currently meets criteria for a Conduct Disorder. Current psychotic symptoms. Substance dependence in the last 3 months. Significant medical condition that would contraindicate the use of an antidepressant. Pregnancy Past treatment with Citalopram for major depression

Sites / Locations

  • Sunnybrook Health Sciences Centre

Outcomes

Primary Outcome Measures

Relapse - subject meets criteria for an episode of major depression for 2 weeks or more.

Secondary Outcome Measures

Full Information

First Posted
November 3, 2005
Last Updated
September 18, 2006
Sponsor
Sunnybrook Health Sciences Centre
search

1. Study Identification

Unique Protocol Identification Number
NCT00249886
Brief Title
Discontinuation Study Of Citalopram (Antidepressant) in Depressed Adolescents
Study Type
Interventional

2. Study Status

Record Verification Date
November 2005
Overall Recruitment Status
Withdrawn
Study Start Date
September 2002 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
November 2006 (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Sunnybrook Health Sciences Centre

4. Oversight

5. Study Description

Brief Summary
The purpose of the study is to evaluate whether it is advantageous for adolescents who have recovered from depression after a 6 to 12 week course of antidepressant treatment to stay on the treatment a further 6 months or is it just as helpful to stop the medication after recovery. The hypothesis is that adolescents with major depression who recover from the 6 to 12 week trial of citalopram will be less likely to have a recurrence of depression over a 6 month period if continued on the citalopram as compared to those who discontinue the medication.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Major Depression

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
60 (false)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Citalopram
Primary Outcome Measure Information:
Title
Relapse - subject meets criteria for an episode of major depression for 2 weeks or more.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
13 Years
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Diagnosis of major Depression. Age 13-18. A score of > 16 on the 17 item Hamilton Depression Scale or a score of > 12 on the 17 items plus a score of >7 on the atypical items. Males and females. Outpatient at initiation of double blind treatment phase. Ability to give informed consent. Exclusion Criteria: Past or current hypomanic or manic episode. Currently meets criteria for a Conduct Disorder. Current psychotic symptoms. Substance dependence in the last 3 months. Significant medical condition that would contraindicate the use of an antidepressant. Pregnancy Past treatment with Citalopram for major depression
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Anthony J Levitt, MD
Organizational Affiliation
Sunnybrook Health Sciences Centre
Official's Role
Principal Investigator
Facility Information:
Facility Name
Sunnybrook Health Sciences Centre
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M4N 3M5
Country
Canada

12. IPD Sharing Statement

Learn more about this trial

Discontinuation Study Of Citalopram (Antidepressant) in Depressed Adolescents

We'll reach out to this number within 24 hrs